Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

Diabetes Care(2022)10.2337/dc21-2034Source: DataRank Database

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials is a research paper published in Diabetes Care (2022). On theSindex it has a DataRank of 1.4. It has been cited 44 times, with 40 citing works in its 1-hop citation network.

N/A

1.4DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access44 citations · 40 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03594110 NCT00885118 NCT00789035 NCT00558571 NCT00749190 NCT01011868 NCT01193218 NCT01210001 NCT01177813 NCT01159600 NCT01289990 NCT01131676 NCT01164501 NCT01370005 NCT01306214 NCT01649297 NCT01947855 NCT02589639
figshare10.2337/figshare.19465484

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)OA: bronzeTopics (19)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 41%Citation Network 59%

Base Score Contribution

0.571

From this paper's citation signal

Citation Network Contribution

0.836

From 31 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 40 citers.

Retardo na progressão da doença renal crônica com o uso de inibidores do sglt2: revisão integrativa
Research Society and Development20234 citations19 referencesContributes 0.085
Diversity, Equity, and Inclusion in Clinical Research: A Path Toward Precision Health for Everyone
Clinical Pharmacology & Therapeutics202262 citations61 referencesContributes 0.068
Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy
Expert Review of Clinical Immunology202418 citations44 referencesContributes 0.067
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers
Naunyn-Schmiedeberg s Archives of Pharmacology202510 citations36 referencesContributes 0.067
Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD
Clinical Journal of the American Society of Nephrology202341 citations58 referencesContributes 0.064

Authors (11)

Adeera Levin ORCID,Masaomi Nangaku ORCID,Takashi Kadowaki ORCID,Rajiv Agarwal ORCID,Sibylle J. Hauske ORCID

Live enrichment

PubMed:35472672 PMC:PMC9210861

CSRD VA

Grant: I01 CX001753

NIDDK NIH HHS

Grant: UC4 DK101108

NIDDK NIH HHS

Grant: U2C DK114886

NIDDK NIH HHS

Grant: U54 DK083912

NIDDK NIH HHS

Grant: UM1 DK100846

NHLBI NIH HHS

Grant: R01 HL126903

National Institutes of Health

Grant: 5UM1DK100846-03

Primary Outcomes in Glomerulonephritis Study (PROGRESS)

National Institutes of Health

Grant: 5R01HL126903-04

ChLorthalidone In Chronic Kidney Disease (CLICK) Study

National Institutes of Health

Grant: 2UC4DK101108-02

PERL: A multi-center clinical trial of allopurinol to prevent GFR loss in T1D

National Institutes of Health

Grant: 1ZIATR000426-01

Developing an Integrated Rare Disease Bioinformatics Resource to Determine Phenotype to Genotype Correlations

National Institutes of Health

Grant: 5I01BX001753-08

What Causes Human Narcolepsy?

Canadian Institutes of Health Research

Grant: unidentified

unidentified

National Institutes of Health

Grant: 2U54DK083912-06

Nephrotic Syndrome Rare Disease Clinical Research Network

National Institutes of Health

Grant: 1U2CDK114886-01

Central Hub for Kidney Precision Medicine

bronzeLicense: CC BY NC SA

publisherhttps://diabetesjournals.org/care/article-pdf/45/6/1445/684191/dc212034.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/45/6/1445/715953/dc212034.pdf

repositoryhttps://scholarworks.indianapolis.iu.edu/bitstreams/b209af4f-8be2-4c4d-9ee1-e6fbe69e939c/download

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9210861

Europe_PMChttps://europepmc.org/articles/PMC9210861

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansDiabetes Mellitus, Type 2HyperkalemiaBenzhydryl CompoundsGlucosidesHypoglycemic AgentsRenal Insufficiency, Chronic

Keywords

Cardiovascular and Metabolic RiskBenzhydryl compoundsChronic renal insufficiencyDiabetes Mellitus, Type 2GlucosidesType 2 diabetes mellitusHumansHyperkalemiaHypoglycemic AgentsRenal Insufficiency, Chronic

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (1)

Effect of Long-term Exercise Training on Physical Performance and Cardiorespiratory Function in Adults With CKD: A Randomized Controlled Trial

N/A

1.4DataRank · unranked

American Journal of Kidney Diseases(2022)

co-cited

10.1053/j.ajkd.2022.06.008

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (11)

Funding (14 grants)

Open Access

Topics

Annotations (Europe PMC)

Related Papers (1)